+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Exploiting evolution to treat drug resistance: combination therapy and the double bind



Exploiting evolution to treat drug resistance: combination therapy and the double bind



Molecular Pharmaceutics 9(4): 914-921



Although many anticancer therapies are successful in killing a large percentage of tumor cells when initially administered, the evolutionary dynamics underpinning tumor progression mean that, often, resistance is an inevitable outcome. Research in the field of ecology suggests that an evolutionary double bind could be an effective way to treat tumors. In an evolutionary double bind two therapies are used in combination such that evolving resistance to one leaves individuals more susceptible to the other. In this paper we present a general evolutionary game theory framework of a double bind to study the effect that such an approach would have in cancer. Furthermore we use this mathematical framework to understand recent experimental results that suggest a synergistic effect between a p53 cancer vaccine and chemotherapy. Our model recapitulates the latest experimental data and provides an explanation for its effectiveness based on the commensalistic relationship between the tumor phenotypes.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053137158

Download citation: RISBibTeXText

PMID: 22369188

DOI: 10.1021/mp200458e


Related references

Exploiting cellular senescence to treat cancer and circumvent drug resistance. Cancer Biology and Therapy 9(3): 166-175, 2010

Evolution of HIV-1 drug resistance in patients failing combination antiretroviral therapy. Zhonghua Yi Xue Za Zhi 90(9): 584-587, 2010

HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. Journal of Acquired Immune Deficiency Syndromes 40(1): 34-40, 2005

Exploiting drug repositioning for discovery of a novel HIV combination therapy. Journal of Virology 84(18): 9301-9309, 2010

Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. Antiviral Therapy 14(3): 359-369, 2009

Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. Aids 21(6): 721-732, 2007

Drug resistance and viral load in NUCA 3002 Lamivudine /zidovudine combination therapy versus ZDV/dideoxycytidine combination therapy in ZDV-experienced patients. INFECTIOUS DISEASES SOCIETY OF AMERICA , NATIONAL INSTITUTES OF HEALTH , CENTERS FOR DISEASE CONTROL AND PREVENTION 3rd Conference on retroviruses and opportunistic infections : 113, 1996

Drug resistance and viral load in NUCA 3002 A comparative trial of lamivudine /zidovudine combination therapy vs ZDV/dideoxycytidine combination therapy in ZDV-experienced patients. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 10(SUPPL 3): S27, 1995

Evolution of HIV drug resistance in zidovudine/zalcitabine- and zidovudine/didanosine-experienced patients receiving lamivudine-containing combination therapy. Antiviral Therapy 3(2): 81-88, 1998

Collateral Resistance and Sensitivity Modulate Evolution of High-Level Resistance to Drug Combination Treatment in Staphylococcus aureus. Molecular Biology and Evolution 32(5): 1175-1185, 2016

Drug-resistance enables selective killing of resistant leukemia cells: Exploiting of drug resistance instead of reversal. Leukemia 13(12): 2031-2035, 1999

Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal. Leukemia 13(12): 2031-2035, 1999

Exploiting multidrug resistance to treat cancer. Cold Spring Harbor Symposia on Quantitative Biology 59: 677-683, 1994

Combination therapy of paclitaxel and cyclopamine polymer-drug conjugates to treat advanced prostate cancer. Nanomedicine 13(2): 391-401, 2016

Single-dose therapy and prevention of drug resistance in rodent trypanosomiasis by the use of drug combination. 15th Meeting of the International Scientific Council for Trypanosomiasis Research and Control, Banjul, The Gambia, 1977: 403-411, 1979